Want to see DERM full AI Analyst Report?
DERM Stock Chart & Stats
$7.53
$0.18(2.91%)
At close: 4:00 PM EDT
$7.53
$0.18(2.91%)
Day’s Range― - ―
52-Week Range$4.31 - $9.56
Previous Close$6.37
Volume133.76K
Average Volume (3M)190.06K
Market Cap
$221.84M
Enterprise Value$194.55
Total Cash (Recent Filing)$25.64M
Total Debt (Recent Filing)$25.54M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding22,224,396
10 Day Avg. Volume102,023
30 Day Avg. Volume190,056
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.93
Price to Sales (P/S)3.05
P/FCF Ratio-15.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.50Price Target Upside79.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.07
Revenue Forecast (FY)$82.61M
Bulls Say, Bears Say
Bulls Say
Revenue And Amrozi GrowthStrong year-over-year revenue growth, supported by rising Amrozi demand, indicates expanding commercial traction rather than reliance on a stagnant product base. Continued prescription growth can improve operating leverage and provide a durable foundation for broader dermatology portfolio commercialization.
Expanding Prescriber BaseA rapidly expanding prescriber base strengthens Journey Medical’s commercial reach and supports recurring prescription demand. Broader physician adoption can make future sales growth more durable by increasing the number of healthcare providers familiar with and actively using Amrozi.
Improving Operating ProfitabilityThe combination of a 67% gross margin and positive quarterly EBITDA shows improving operating economics as revenue scales. If commercial momentum continues, this progress could help the company transition from substantial losses toward self-funded growth and greater financial flexibility.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow indicates that reported commercial progress has not yet translated into reliable cash generation. Continued cash burn can constrain investment in products and sales capacity, increasing the importance of sustained execution to reach self-funding operations.
Payer Access FrictionLimited high-quality formulary coverage can slow prescription conversion and create reimbursement barriers for patients and physicians. Because further ASP improvement and sales acceleration depend on additional payer wins, execution on access remains a material constraint on durable growth.
Profitability Remains UnprovenDespite materially narrower losses and positive EBITDA in Q2, Journey Medical has not yet demonstrated consistent GAAP profitability. Ongoing operating and net losses leave the business more dependent on continued revenue growth, margin discipline, and successful commercialization.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corp’s price range in the past 12 months?
Journey Medical Corp lowest stock price was $4.31 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corp’s market cap?
Journey Medical Corp’s market cap is $221.84M.
When is Journey Medical Corp’s upcoming earnings report date?
Journey Medical Corp’s upcoming earnings report date is Nov 11, 2026 which is in 64 days.
How were Journey Medical Corp’s earnings last quarter?
Journey Medical Corp released its earnings results on Aug 12, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.012.
Is Journey Medical Corp overvalued?
According to Wall Street analysts Journey Medical Corp’s price is currently Undervalued.
Does Journey Medical Corp pay dividends?
Journey Medical Corp does not currently pay dividends.
What is Journey Medical Corp’s EPS estimate?
Journey Medical Corp’s EPS estimate is 0.02.
How many shares outstanding does Journey Medical Corp have?
Journey Medical Corp has 22,224,396 shares outstanding.
What happened to Journey Medical Corp’s price movement after its last earnings report?
Journey Medical Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went up 3.421%.
Which hedge fund is a major shareholder of Journey Medical Corp?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (79.28% Upside)
$13.50 (79.28% Upside)
Blogger Sentiment
Bullish
DERM Sentiment 60%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Journey Medical Corp
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
DERM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum—notably strong top-line growth (total revenue +23% YoY), robust Amrozi prescription growth (≈20% sequential), expanding prescriber footprint (>40% increase since 2025 year-end), positive EBITDA and materially narrowed GAAP losses—while also acknowledging remaining headwinds around payer friction (only ~38% high-quality formulary coverage), some product-level softness (QBREXZA in the quarter), and timing uncertainty for international out-licensing. Management highlighted continued investments (new reps, marketing, a new product launch) to capitalize on momentum. On balance, the positive operational and financial progress substantially outweighs the noted challenges.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$13.50
▲(79.28% Upside)
Technical Analysis
Ownership Overview
19.48% Insiders
14.17% Mutual Funds
32.15% Other Institutional Investors
30.92% Public Companies and
Individual Investors